Explore our flagship recombinant peptides, custom building blocks, and clinical-grade raw materials optimized for global pharmaceutical development.
Comprehensive chemical evaluation, molecular characterization, and structural insights for high-purity Human Growth Hormone manufacturing.
CAS 12629-01-5 corresponds to recombinant Somatropin (Human Growth Hormone), a single-chain polypeptide composed of 191 amino acid residues. It features two intramolecular disulfide bonds (Cys53-Cys165 and Cys182-Cys189) critical for maintaining its native 3D tertiary structure and receptor-binding affinity.
Produced primarily via genetically engineered Escherichia coli host systems or eukaryotic cell lines (e.g., Pichia pastoris), ensuring accurate secretory expression that avoids N-terminal methionine retention and yields identity to human pituitary-derived growth hormone.
Strict monitoring of high-molecular-weight aggregates, deamidated forms, oxidized variants, and host cell protein (HCP) residues. High-purity CAS 12629-01-5 requires stable lyophilization parameters to guarantee prolonged shelf life under cold-chain conditions.
| Analytical Parameter | Pharmacopoeial Standard (EP / USP) | Gentolex Production Standard | Testing Methodology |
|---|---|---|---|
| CAS Number | 12629-01-5 | 12629-01-5 Verified | CAS Registry Index |
| HPLC Monomer Purity | ≥ 96.0% | ≥ 99.2% | SEC-HPLC & RP-HPLC |
| Molecular Mass | 22,125 Da (± 2 Da) | 22,124.8 Da | ESI-TOF Mass Spectrometry |
| Host Cell Proteins (HCP) | < 100 ppm | < 5 ppm | ELISA / LC-MS/MS |
| Bacterial Endotoxins | < 5.0 IU/mg | < 0.5 IU/mg | LAL Kinetic Chromogenic Test |
| Specific Biological Activity | ≥ 3.0 IU/mg | 3.15 - 3.30 IU/mg | In vitro Bio-Assay / Nb2 Cell Line |
Analyzing global procurement trends, biopharmaceutical shifting demands, and supply chain expansion for CAS 12629-01-5.
The worldwide industrial demand for CAS 12629-01-5 (Somatropin API) has experienced accelerated growth driven by expanded clinical indications, anti-aging metabolic research, and pediatric growth deficiency therapies. Commercial pharmaceutical entities, generic manufacturers, and contract development research organizations (CDMOs) require high-volume, highly reproducible API supplies that strictly conform to international pharmacopoeial standards (USP, EP, JP, ChP).
Key geographic growth nodes include North America and Western Europe, where ongoing drug-delivery innovation (such as long-acting depot injections and oral peptide technologies) demands ultra-pure monomeric Somatropin. Concurrently, emerging pharmaceutical hubs across Latin America (specifically supported by regional operations like our Mexico node) and Africa (anchored by our South Africa facility) are scaling local formulation capabilities, creating strong demand for integrated Finished Dosage Form (FDF) licensing out, bulk intermediate supply, and technology transfer packages.
Bridging next-generation expression technologies, green bioprocessing, and controlled release delivery platforms.
Implementation of fed-batch fermentation with automated dissolved oxygen (DO) and nutrient feeding control. This boosts biomass yields of E. coli expressing Somatropin precursor, increasing overall space-time yield while decreasing batch-to-batch variation.
Transitioning from traditional batch folding to multi-stage continuous inclusion body refolding columns coupled with multi-column chromatography (MCC). This process minimizes oxidative stress and reduces dimer/aggregate formation to below 0.3%.
Engineering site-specific mono-PEGylated variants and microparticle encapsulations of Somatropin. These innovations enable weekly or bi-weekly dosing regimes, improving patient compliance while protecting peptide stability.
Connecting global pharmaceutical partners with certified API manufacturing, custom peptide synthesis, and end-to-end supply chain integration.
Gentolex specializes in commercial API manufacturing, scalable solid-phase (SPPS) and liquid-phase (LPPS) peptide synthesis, as well as complex recombinant polypeptide production under cGMP standards.
We provide full Finished Dosage Form (FDF) dossier licensing, analytical method transfers, formulation troubleshooting, and turn-key laboratory setup for pharmaceutical companies worldwide.
Serving clients in over 10 countries with key international representative bases in Mexico and South Africa, guaranteeing reliable cold-chain delivery and localized regulatory assistance.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions. Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide. For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
Rigorous cGMP controls, comprehensive DMF document filings, and localized regulatory frameworks for international partners.
Every commercial batch of CAS 12629-01-5 comes with a complete Certificate of Analysis (CoA), HPLC purity chromatograms, Mass Spectrometry (MS) verification, Endotoxin certification, and access to Drug Master File (DMF) filing documentation compatible with US FDA and EMA guidelines.
Somatropin APIs are highly temperature-sensitive. Gentolex operates validated cold-chain logistics (-20°C standard storage and 2–8°C insulated transport) monitored via real-time temperature tracking to prevent protein denaturing or aggregate formation during international transit.
With direct representative centers located in Mexico and South Africa, we facilitate swift regional customs clearance, local technical consultations, regulatory submittal guidance, and seamless procurement solutions across regional healthcare sectors.
Stay informed with the latest updates from our research labs, peptide engineering breakthroughs, and industry developments.
Answers to essential technical, regulatory, and purchasing questions regarding Somatropin API manufacturing.
Discover our extended line of high-purity peptides, novel therapeutic compounds, and commercial ingredients.
